VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
Robin Kate Kelley,Thomas Yau,Ann‐Lii Cheng,Ahmed O. Kaseb,Shukui Qin,Andrew X. Zhu,Stephen L. Chan,Wattana Sukeepaisarnjaroen,В. В. Бредер,Gontran Verset,Edward Gane,Ivan Borbath,J.D. Gomez Rangel,Philippe Merle,Fawzi Benzaghou,Kamalika Banerjee,Saswati Hazra,Jonathan W. Fawcett,Lorenza Rimassa
The multikinase inhibitor C has shown promising clinical activity in combination with immune checkpoint inhibitors, including A, in multiple tumor types. COSMIC-312 (NCT03755791) is evaluating C+A vs S as first-line systemic treatment for aHCC.
迷路的问儿
归尘
有人
嗯哼
藤椒辣鱼
MchemG
jyy
Henry
龍一
oydent
楚楚
俞无声
若雨凌风
Cochrane
VDC
小红薯7XJ9B2Q4
眯眯眼的衬衫
qrwyqjbsd
冷艳的立果
YifanWang
皖公网安备34019202002308
